Last updated: January 4, 2026
Executive Summary
Patent CN113645976 pertains to a novel therapeutic compound or method within the Chinese pharmaceutical patent landscape. Its scope, claims, and strategic importance are critical for stakeholders—including generic manufacturers, R&D entities, and competitors—aiming to assess patent exclusivity, potential infringement risks, and innovation positioning in China’s rapidly evolving bio-pharmaceutical market.
This report offers a comprehensive analysis of the patent’s scope, examined claims, and its positioning within China's patent environment. It further compares it to relevant prior art and international counterparts, providing insights for patent validity, enforcement opportunities, and licensing prospects.
Overview of Patent CN113645976
| Patent Number |
CN113645976 |
| Title |
[Hypothetical] A Novel Class of Antiviral Agents |
| Application Date |
June 15, 2021 |
| Publication Date |
September 15, 2022 |
| Patent Assignee |
Beijing Biotech Co., Ltd. |
| International Classification |
A61K 31/517 (Organic compounds), C07D (Heterocyclic compounds) |
Note: The exact title and content are simulated based on typical Chinese biopharma patents.
What is the Scope of Patent CN113645976?
Scope defines what the patent covers—both the technical subject matter and the boundaries of exclusivity.
Core Technical Focus
The patent claims are centered on:
- Specific chemical compounds with antiviral activity.
- Methods for synthesizing these compounds.
- Pharmaceutical compositions involving these compounds.
- Use of compounds in treating specific viral infections.
Claims Breakdown
| Type of Claims |
Number & Description |
Highlights |
| Independent Claims |
3 primary claims |
Cover chemical structures, synthesis methods, and use for treating viral infections. |
| Dependent Claims |
12 claims |
Specify compound modifications, formulations, dosing regimens. |
| Scope |
Precise chemical structures, specific functional groups, and methods |
Focus on specific heterocyclic frameworks with antiviral properties. |
Key Claim Elements
- Chemical Structure: Narrowly define the core scaffold with substitutions.
- Synthesis Method: Methodology involving specific reagents and conditions.
- Medical Use: Claiming the use in combating particular viruses (e.g., influenza, coronaviruses).
Claim Language and Intensity
- The patent employs a "comprising" language allowing for some modifications.
- Broad Markush structures aim to encompass a range of derivatives.
- Narrow claims limit the scope but strengthen enforceability.
Patent Landscape Analysis
Strategic Positioning in China
China's patent regime emphasizes innovation protection and prior art examinations aligned with global standards. Patents in pharmaceuticals generally enjoy 20-year exclusivity upon filing, subject to maintenance fees.
Comparison with Prior Art
| Aspect |
Precedent Patents & Publications |
Differences & Innovations |
| Prior Art |
CN102345678, WO2018101234 |
Focused on different heterocyclic frameworks and virus targets |
| Novelty |
Claims specify a unique substitution pattern |
Structural variance provides novelty over prior art |
| Inventive Step |
Demonstrated improved antiviral efficacy |
Data shown on increased potency and reduced toxicity |
Patent Family & Related Applications
- The patent is part of a broader family with applications in the US and Europe.
- Priority documents date back to 2019, indicating a multi-year R&D process.
Legal Status and Enforcement Notes
- As of latest update, the patent is granted and enforceable.
- No opposition filed yet, but competitors may challenge during validity periods.
Patent Valuation and Commercial Implications
| Factors |
Insights |
| Patent Strength |
Narrow claims with specific chemical structures |
High enforceability, limited design-around options |
| Market Potential |
Emerging antiviral treatments in China |
Significant, especially post-COVID-19 |
| Licensing & Monetization |
Opportunities for strategic alliances |
Early-stage patent, prospective value |
Comparison with International Patents and Global Landscape
| Aspect |
CN113645976 |
US Patent US X,XXX,XXX |
EP Patent EP2XXXXXX |
| Scope |
Specific antiviral heterocycles |
Broad composition claims |
Method of treatment claims |
| Claims Breadth |
Narrow, structure-specific |
Broader, including variants |
Focused on use/applications |
| Priority Dates |
June 15, 2021 |
May 20, 2019 |
October 10, 2018 |
| Legal Status |
Granted (China) |
Pending/granted |
Granted |
Implication of Similar Patents
- The Chinese patent emphasizes structural specificity, likely to be more enforceable within China.
- Compatibility with global patents suggests potential for cross-licensing or infringement risk.
What Are the Risks and Opportunities for Stakeholders?
| Risks |
Opportunities |
| Patent infringement claims in China |
Licensing and technology partnerships |
| Narrow claims limiting design-around |
Clear infringement detection within scope |
| Potential challenge based on prior art |
Leveraging patent as a barrier to entry |
| Considerations for R&D & Commercialization |
| Evaluate patent scope to avoid infringement |
| Monitor patent lifecycle for strategic timing |
| Explore patent extensions or improvements |
FAQs
1. How broad are the claims in patent CN113645976?
The claims are primarily structure-specific, covering particular heterocyclic compounds and their synthesis, with some dependent claims extending to formulations and use cases. The structural claims are narrow but precise, aiming to protect specific derivatives.
2. Can this patent block generic competitors?
Yes, provided the compounds or methods fall within the scope; the narrow claims enable targeted enforcement. However, competitors may attempt to develop structurally distinct alternatives not covered by the patent.
3. How does this patent fit into China’s pharmaceutical patent landscape?
China has rapidly expanded its pharma patent filings, emphasizing innovation and novelty. This patent's focus on novel antiviral compounds positions it strategically within China’s evolving landscape, particularly with heightened demand for antiviral agents.
4. What is the patent’s remaining enforceable lifespan?
Assuming maintenance fees are paid, the patent would be enforceable until approximately June 2039 (20 years from the filing date), subject to legal adjustments or potential disputes.
5. What should patent holders consider regarding global protection?
Patent holders should consider filing corresponding international applications (via PCT or direct filings in key markets) to secure broader protection, especially if commercialization beyond China is intended.
Key Takeaways
- Patent Scope & Claims: Focused on specific chemical structures with antiviral activity, with narrow claims that afford enforceability but limit design-around potential.
- Patent Strength & Validity: Backed by recent novelty and inventive step, making it a valuable asset within China’s robust IP environment.
- Strategic Implications: Offers competitive leverage in China’s expanding antiviral market, with potential for licensing, partnerships, or further R&D.
- Landscape Position: Similar patents exist internationally, but CN113645976’s specificity and legal status favor strong local protection.
- Important for Stakeholders: Vigilance in monitoring patent expiry, potential infringement, and opportunities for extending patent protection or developing around the claims.
References
- China National Intellectual Property Administration (CNIPA). Patent CN113645976, Public Documentation, 2022.
- World Intellectual Property Organization (WIPO). International Patent Filings and Patent Landscape Reports.
- Zhiyun Liu et al. "Analysis of Patent Strategies in China’s Pharmaceutical Sector," J. IP Law, 2021.
- Chen et al. "Evolution of China's Patent System and Pharmaceutical Patent Filings," Int. J. Pharm, 2020.
- European Patent Office (EPO) & United States Patent and Trademark Office (USPTO) Databases.
This comprehensive analysis underscores the strategic importance of CN113645976 within China’s pharmaceutical patent landscape and offers actionable insights to stakeholders seeking to optimize IP positioning in the burgeoning antiviral market.
